BioMarin Pharmaceutical Inc. Stock News

These biopharma stocks are taking a big hit because of the COVID-19 pandemic.

An overall market rebound and a presidential press conference carried several biotech and pharmaceutical stocks markedly higher.

BioMarin's stock isn't escaping the marketwide sell-off. Savvy investors, though, may want to take advantage of this latest decline in the drugmaker's shares.

Even healthcare companies can't escape the overall market downturn.

The long-term outlook is rosy for these five biotech stocks. They have the pipelines, partners and marketed drugs to provide years of growth for investors.

BioMarin (BMRN) announces mixed results for the fourth quarter of 2019, beating estimates for earnings while missing the same for sales.

Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean-Jacques Bienaimé on Q4 2019 Results - Earnings Call Transcript

BioMarin (BMRN) delivered earnings and revenue surprises of 19.05% and -1.61%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

The gene therapy maker's novel medicine has the potential to take over a highly competitive market and offer growth opportunities for investors.

Key orphan disease drugs, Vimizim and Kuvan, are likely to have driven BioMarin's (BMRN) fourth-quarter top line.

BioMarin (BMRN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

The agency expects to make a decision by Aug. 21, 2020.

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

With sales of $1.6 billion over the past year, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will get a hefty revenue boost with the introduction of its hemophilia A therapy, which is expected later this

These stocks could thump the broader markets this year.